Montreal (QC, Canada) Sept 15th 2026 – Telescope Therapeutics announced today that it has been selected by Capital BioVentures to join the ASCENT26 Program, a curated accelerator for high-potential Canadian life sciences companies. ASCENT26 provides therapeutic early-stage companies with the strategic, corporate, and product development frameworks required to build successful companies and investor traction. This initiative is supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).
“Being selected by Capital BioVentures is a catalyst and strengthens our execution momentum as we advance the development of our candidate. ASCENT's mentorship and network will further support our upcoming Seed financing round while reinforcing our commitment to delivering value to investors and transformative therapies to patients battling threatening fibrotic diseases,’’ said Myriam Lavoie, CEO at Telescope Therapeutics.
Telescope focuses on developing novel therapeutic candidates selectively reshaping the fibrotic response, halting the progression toward organ failure while preserving critical tissue repair mechanisms. To drive this drug discovery pipeline, the company leverages a human-relevant preclinical platform pairing patient-derived induced pluripotent stem cell disease models with real-time biosensors. By profiling disease biology directly in human systems early in development,Telescope identifies and advances high-conviction therapeutic candidates with superior clinical translatability.
“Telescope has the science, platform, and potential to attract the investment needed to advance its pipeline. We’re excited to welcome the team to ASCENT26 and help position the company for its next stage of growth and investor engagement,” said Dr. Jeff Smirle, Executive Director of Capital BioVentures.
About Telescope Therapeutics
Telescope Therapeutics is a discovery-stage biotechnology company developing targeted therapies to reshape the fibrotic response and prevent organ failure. Powered by a predictive platform integrating patient-derived induced pluripotent stem cell (iPSC) models with advanced biosensors, Telescope decodes human disease biology early to advance high-conviction therapeutic candidates for fibrotic diseases.
For more information, visit www.telescopetherapeutics.com
About Capital BioVentures
Capital BioVentures (CBV) is a not-for-profit wet-lab accelerator located in Ottawa that offers early-stage funding and resources to Canadian companies. The organization provides access to specialized drug and corporate development professionals, as well as high-quality laboratory space, equipment, and non-dilutive funding. Backed by investments from FedDev Ontario and the National Research Council’s Industrial Research Assistance Program, CBV provides full-service supports, allowing small- and medium-sized enterprises (SMEs) to develop their products and expand their businesses.
To learn more about Capital BioVentures, visit www.capitalbioventures.ca
Media Contacts: Myriam Lavoie, MS, Telescope Therapeutics (CEO) myriam.l@telescopetherapeutics.com, and Tazmeen Khan, Capital Bioventures (Director Communications) taz@capitalbioventures.ca
